NetworkNewsBreaks Archive - Page 509 of 553

FridayJan 27, 2017 1:46 pm

NetworkNewsBreaks – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) Tackles Lactose Intolerance, Metabolic Syndrome with RP-G28

Ritter Pharmaceuticals (NASDAQ: RTTR) is a specialty pharmaceutical company developing therapeutics that modulate the gut microbiome to treat gastrointestinal diseases. The company’s first novel microbiome modulator, RP-G28, is currently in a phase 2b/3 study in humans for the treatment of lactose intolerance. More than one billion people suffer from lactose intolerance globally, and the company believes RP-G28 has the potential to become the first FDA-approved drug for the treatment of the disease. In previous human studies, RP-G28 has demonstrated significant beneficial changes to the gut microbiome that have been associated with supporting metabolic health. Recently, the company announced a collaborative…

FridayJan 27, 2017 12:55 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on January 27, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: VEND 50.15% – News: Issues letter to shareholders PULM 34.01% – News: RDI issues research report ESSI 8.31% – News: Moving on momentum of growth capital financing, operational updates RYES 6.73% – News: Acquires major past producing gold mine AUPH 6.56% – News: Selects Worldwide Clinical Trials as CRO for phase 3 lupus nephritis trial PURE 3.37% – News: Publishes Norovirus Technical Bulletin in response to recent norovirus media coverage IMMU 1.97% – News:…

FridayJan 27, 2017 12:15 pm

NetworkNewsBreaks – Novan, Inc. (NASDAQ: NOVN) Shares Plunge on Inconsistent Topline Results from SB204 Phase 3 Pivotal Trials

Novan (NASDAQ: NOVN) shares dropped 75% this morning following the release of top-line results from the two, replicate phase 3 pivotal clinical trials for the company’s topical nitric oxide-releasing product candidate SB204 in the treatment of acne vulgaris. In the intent-to-treat analysis, SB204 demonstrated statistical significance on all three co-primary endpoints in NI-AC302, but it demonstrated statistical significance on only one of three co-primary endpoints in NI-AC301. The three co-primary endpoints included the absolute changes in inflammatory and non-inflammatory lesion counts and proportion of patients achieving success, “clear” or “almost clear,” on the Investigator Global Assessment (IGA) at week 12. …

ThursdayJan 26, 2017 1:36 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on January 26, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: SGLB 37.61% – News: Signs commercial agreement with Pratt & Whitney PLFX 15.38% – News: Enters joint venture with Augmented Reality Technology Specialist Augmently, Inc. QPAG 12.50% – News: Expands its self-service payment solutions ANY 7.55% – News: Launches second advertising and lead generation campaign for Glassware 2.0™ INVT 6.67% – News: Reaches agreement with preferred stockholders to extend redemption timeframe KNDI 6.03% – News: JV’s EV Model K11 receives MIIT recommendation MTNB 5.47%…

ThursdayJan 26, 2017 1:36 pm

NetworkNewsBreaks – Gopher Protocol, Inc. (GOPH) Competes in $1B GPS Personal Tracking Industry with Innovative GuardianPatch

Gopher Protocol (OTCQB: GOPH) develops real-time, self-learning (heuristic) mobile technologies. In collaboration with partner Guardian Patch LLC, Gopher has developed Guardian Patch Location Technology. The company’s patented Integrated Circuit (IC) GopherInsight technology is part of the muscle behind the mobile app designed to track valuables such as electronics or other objects, loved ones or even pets. In November 2016, the GuardianPatch patent was finalized and filed. The product is expected to hit the market in 2017, aligned with the current boom in GPS personal tracking devices and applications, a market expected to break $1 billion in 2017. To learn more,…

ThursdayJan 26, 2017 1:34 pm

NetworkNewsBreaks – Kindred Biosciences, Inc.’s (NASDAQ: KIN) Strategy to Capture its Share of $7.5B Animal Health Market

Kindred Biosciences (NASDAQ: KIN) is a development-stage biopharmaceutical company taking aim at the $7.5 billion animal health market, specifically focusing on therapies for pets. The company has established a simple, yet effective, strategy to capture its share of the market: leverage investments made in human pharmaceutical R&D to develop therapies that offer the benefits of lower risk, lower cost, and shorter time-to-market. Kindred currently has in development an exciting pipeline of more than 20 programs of high-value products for dogs, cats and horses. The company’s lead candidates are Mirataz™, a weight loss product for cats, and Zimeta™ to treat fever…

ThursdayJan 26, 2017 1:31 pm

NetworkNewsBreaks – Apricus Biosciences, Inc. (NASDAQ: APRI) Continues to Advance Erectile Dysfunction Treatment on Global Scale

Apricus Biosciences (NASDAQ: APRI) is focused on advancing the development and commercialization of its innovative, life-improving treatment products in urology and rheumatology. The company’s pipeline includes Vitaros®, a locally applied topical cream for the treatment of erectile dysfunction, a condition affecting roughly 150 million men worldwide. Containing alprostadil in combination with the company’s novel excipient, Vitaros delivers a rapid onset with significant efficacy and an encouraging safety profile. In a study of more than 3,000 patients, Vitaros demonstrated positive, clinically meaningful responses in measures of erectile function. The FDA recently determined that Vitaros, under current regulations, is now considered a…

ThursdayJan 26, 2017 1:26 pm

NetworkNewsBreaks – Regulatory Approvals Mark Significant Milestones for Trendlines Group Ltd.’s (TRNLY) Gordian Surgical

Gordian Surgical, a medical portfolio company of Trendlines Group Ltd. (OTCQX: TRNLY), is making significant advances in the way surgical procedures are performed with its TroClose1200™, which in the fourth quarter of 2016 was awarded both U.S. FDA regulatory clearance and CE Mark certification. TroClose1200 was designed to provide surgeons "two-in-one" functionality. The device acts as a trocar, through which surgical instruments enter the abdomen; and as a device to close internal incisions made during surgery. It works by enabling the insertion of sutures into the tissue at the beginning of the procedure and is anchored to remain in place…

ThursdayJan 26, 2017 1:20 pm

NetworkNewsBreaks – Asterias Biotherapeutics (NYSE: AST): AST-OPC1 Efficacy Results Demonstrate Life-changing Potential for Spinal Cord Injury Patients

With an eye on FDA discussions later this year, biotech Asterias (NYSE: AST) is harnessing the potential of regenerative medicine to improve the quality of life of patients with spinal cord injuries (SCI). Recent efficacy results from the ongoing phase 1/2a clinical trial showed that SCI patients treated with the company’s AST-OPC1 cells demonstrated improved ability to use their arms, hands and fingers. Company CEO Steve Cartt in a press release called the results encouraging as Asterias plans for discussions with the FDA in mid-2017 to determine the appropriate strategy for regulatory approval. According to the World Health Organization, between…

ThursdayJan 26, 2017 1:17 pm

NetworkNewsBreaks – Fuwei Films (NASDAQ: FFHL) Shares Surge on Potential of New Polyester Film Sales Contract

Shares of Fuwei Films (NASDAQ: FFHL) are up 54% this morning on news the company has signed an annual sales contract with Eternal Electronic Material (Guangzhou) Co., Ltd., an existing costumer that purchases polyester film for printed circuit boards (PCB). Fuwei expects that the new contract for 2017 will increase the total polyester film for PCB sales in the first quarter of the year by approximately 34.5% compared to the same period of 2016. "Our company will continue to execute a portfolio of products that optimizes a higher margin strategy. We intend to continue to leverage our R&D capabilities and…

Financial news and publishing for public and private companies

Contact us: 212.418.1217

NetworkNewsBreaks